カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界の粒子線療法市場（～2028年）：種類別（陽子線治療、重粒子線治療）、製品別（サイクロトロン、シンクロトロン、シンクロサイクロトロン）、サービス別、システム別（シングルルーム、マルチルーム）、がん種類別（小児がん、前立腺がん）、用途別（治療、研究）

◆英語タイトル：Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028
	◆商品コード：MD6747-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2023年11月9日 ◆ページ数：196 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥1,010,800	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,238,800	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

“世界の粒子線療法市場は2023年の7億米ドルから2028年には11億米ドルに達し、予測期間中の年平均成長率は8.2％になると予測”粒子線療法市場の急成長が予測される背景には、がんの増加、技術の進歩、がんに関する個人の意識の向上、がん研究への資金提供の増加などがあります。

“2023年から2028年の予測期間において、小児用アプリケーション分野が最も高いCAGRを記録”
粒子線療法市場は、がんの種類に基づいて、小児がん、乳がん、肺がん、前立腺がん、頭頸部がん、その他のがんに区分されます。2022年に最も高い成長率を示したのは小児がんです。小児がんの増加は、遺伝的素因、乳幼児の発育要因、未熟な免疫系、環境暴露、母親要因、細胞の脆弱性などの理由によるものです。

“予測期間中、アジア太平洋が市場の大幅な成長率を記録”
予測期間2023-2028年では、アジア太平洋が予測期間中に市場で著しい成長率を記録する見込みです。アジア太平洋は、インド、中国、日本、オーストラリア、韓国、Roアジア太平洋で構成されています。アジア太平洋（アジア太平洋）地域は、粒子線療法市場の市場成長率が大幅に上昇しています。この成長にはいくつかの要因があります。
アジア太平洋諸国で見られる人口動態の成熟化により、治療に関連する副作用を最小限に抑えることを特徴とする効率的ながん治療法の必要性が強調されています。粒子線療法市場の精密さ主導の特性との共鳴は、市場展望を強化する上で極めて重要な役割を担っています。
アジア太平洋の病院では多言語による患者ケアを提供しており、粒子線療法市場のような高度な治療へのアクセスも可能であることから、特に多様な患者の間で、この地域に独自の魅力を与えています。このような言語による包括性と最先端の医療介入との融合は、この地域の好まれている医療目的地としての望ましさを著しく高め、その結果、医療市場ランドスケープにおける競争力を強化し、粒子線療法市場の隆盛を後押ししています。

本レポートの主な参加企業の内訳は以下の通りです：
- 企業タイプ別：ティア1-40％、ティア2-30％、ティア3-30％
- 役職別：Cレベル-27％、ディレクターレベル-18％、その他-55％
- 地域別：北米-50％、ヨーロッパ-20％、アジア太平洋-15％、中南米-10％、中東・アフリカ-5％

粒子線療法市場の主要企業は、Varian Medical Systems, Inc.(US), IBA Worldwide(EU) and Hitachi (Japan) などが含まれます。

調査範囲：
- 本レポートでは、粒子線療法市場をタイプ、システム、製品、用途、癌の種類、地域に基づいて調査しています。
- 市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。
- 利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供します。
- 微小市場の成長動向、展望、世界の粒子線療法市場への貢献に関して調査しています。
- 主要5地域に関して市場セグメントの収益を予測しています。

レポート購入の主な利点：
本レポートは、包括的なデータの徹底的な分析を通じて、粒子線療法市場における投資評価の実行可能性について、市場リーダー/新規参入企業/小規模企業の助けとなるため、強固なリスク評価が容易になり、十分な情報に基づいた投資決定が可能になります。用途、エンドユーザー、地域別に細分化された詳細な市場分析により、的確なセグメントターゲティングのためのテーラーメイドの洞察が得られます。また、極めて重要なトレンド、成長触媒、課題、展望を網羅的に評価し、鋭い洞察力で戦略的意思決定を後押しします。

本レポートは、以下のポイントに関する洞察を提供します：
- 粒子線療法市場の成長に影響を与える主な促進要因（がん患者人口の増加、がん管理に対する政府の取り組みの増加、放射線治療による非侵襲的治療の進歩）、阻害要因（熟練した放射線科医/腫瘍医の不足、粒子線療法の高コスト、治療のための画像技術の複雑さ）、機会（新興国における主要企業の拡大、発展途上国における医療費の増加）、課題（代替技術の利用可能性）の分析を提供しています。
- 製品開発/イノベーション：粒子線療法市場における今後の技術、研究開発活動、新製品・サービスの発売に関する詳細な洞察を記載しています。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、さまざまな地域の粒子線療法市場を分析しています。
- 市場の多様化：粒子線療法市場における新製品、未開拓地域、最新動向、投資に関する詳細情報を掲載しています。
- 競合評価： Varian Medical Systems, Inc.(アメリカ)、IBA Worldwide(EU)、日立製作所(日本)などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価を提供しています。

1.　イントロダクション
2.　調査方法
3.　エグゼクティブサマリー
4.　プレミアムインサイト
5.　市場概要
6.　世界の粒子線療法市場規模：製品・サービス別
7.　世界の粒子線療法市場規模：種類別
8.　世界の粒子線療法市場規模：システム別
9.　世界の粒子線療法市場規模：用途別
10.　世界の粒子線療法市場規模：がん種類別
11.　世界の粒子線療法市場規模：地域別
12.　競争環境
13.　企業情報
14.　付録

❖ レポートの目次 ❖

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 INCLUSIONS & EXCLUSIONS 29
1.4 MARKET SCOPE 29
1.4.1 MARKETS COVERED 29
1.4.2 REGIONS COVERED 30
1.4.3 YEARS CONSIDERED 30
1.4.4 CURRENCY CONSIDERED 31
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 31
1.5 STAKEHOLDERS 31
1.6 SUMMARY OF CHANGES 31
1.6.1 RECESSION IMPACT: PARTICLE THERAPY MARKET 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 33
2.1.1.1 Key data from secondary sources 34
2.1.2 PRIMARY DATA 35
2.1.2.1 Key primary sources 35
2.1.2.2 Key data from primary sources 36
2.1.2.3 Breakdown of primaries 36
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 36
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION 37
2.1.2.4 Key industry insights 37
2.2 MARKET SIZE ESTIMATION 38
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 39
FIGURE 5 SUPPLY-SIDE ANALYSIS 39
FIGURE 6 TOP-DOWN APPROACH 40
FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41
FIGURE 8 CAGR PROJECTIONS 42
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 43
FIGURE 9 DATA TRIANGULATION METHODOLOGY 43
2.4 RESEARCH LIMITATIONS 44
2.4.1 SCOPE-RELATED LIMITATIONS 44
2.4.2 METHODOLOGY-RELATED LIMITATIONS 44
2.5 RISK ASSESSMENT 44
2.6 STUDY ASSUMPTIONS 45
2.6.1 IMPACT OF RECESSION ON PARTICLE THERAPY MARKET 45
3 EXECUTIVE SUMMARY 46
FIGURE 10 PARTICLE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 46
FIGURE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 12 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 13 PARTICLE THERAPY MARKET, BY SYSTEM, 2023 VS. 2028 (USD MILLION) 48
FIGURE 14 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2023 VS. 2028 (USD MILLION) 49
FIGURE 15 PARTICLE THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 49
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF PARTICLE THERAPY MARKET 50
4 PREMIUM INSIGHTS 51
4.1 PARTICLE THERAPY MARKET OVERVIEW 51
FIGURE 17 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET 51
4.2 REGIONAL MIX: PARTICLE THERAPY MARKET 52
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 52
4.3 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE AND COUNTRY (2022) 53
FIGURE 19 PROTON THERAPY ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022 53
4.4 PARTICLE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 54
4.5 DEVELOPED VS. EMERGING ECONOMIES: PARTICLE THERAPY MARKET 54
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
FIGURE 22 PARTICLE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
5.1.1 DRIVERS 56
5.1.1.1 Advantages of particle therapy over photon therapy 56
5.1.1.2 Growing prevalence of cancer 56
5.1.1.3 Rising adoption of particle therapy in clinical trials 57
5.1.1.4 Increasing number of particle therapy centers worldwide 57
5.1.1.5 Technological advancements 57
5.1.2 RESTRAINTS 58
5.1.2.1 Infrastructural challenges in healthcare facilities 58
5.1.2.2 Affordability and accessibility of treatments 58
5.1.2.3 Unfavorable reimbursement policies and limited insurance coverage for particle therapy 59
5.1.3 OPPORTUNITIES 59
5.1.3.1 Growth potential of emerging economies 59
5.1.4 CHALLENGES 60
5.1.4.1 Difficulties in visualizing tumors during particle therapy procedures 60
5.1.4.2 Potential for unwanted radiation exposure 60
5.2 ECOSYSTEM/MARKET MAP 61
FIGURE 23 PARTICLE THERAPY MARKET: ECOSYSTEM ANALYSIS 61
5.3 PRICING ANALYSIS 61
5.4 SUPPLY CHAIN ANALYSIS 62
FIGURE 24 SUPPLY CHAIN ANALYSIS: PARTICLE THERAPY MARKET 62
5.5 PATENT ANALYSIS 63
5.5.1 PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET 63
FIGURE 25 TOTAL PATENTS GRANTED FROM 2012–2022 64
FIGURE 26 TOP PATENT APPLICANTS IN PARTICLE THERAPY 64
FIGURE 27 TOP PATENT OWNERS IN PARTICLE THERAPY 65
5.6 VALUE CHAIN ANALYSIS 65
FIGURE 28 PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS 66
5.7 TECHNOLOGY ANALYSIS 66
5.8 KEY CONFERENCES & EVENTS IN 2023–2024 67
5.9 REGULATORY LANDSCAPE 68
TABLE 2 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 3 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
TABLE 5 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
TABLE 6 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION 70
5.10 REIMBURSEMENT ANALYSIS 70
TABLE 7 MEDICAL REIMBURSEMENT CODES FOR PARTICLE THERAPY PROCEDURES IN US, 2022 70
5.11 TRADE ANALYSIS 71
TABLE 8 INSTALLED BASE OF RADIOTHERAPY DEVICES 71
5.12 PORTER’S FIVE FORCES ANALYSIS 71
TABLE 9 PARTICLE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 71
5.12.1 THREAT OF NEW ENTRANTS 71
5.12.2 THREAT OF SUBSTITUTES 72
5.12.3 BARGAINING POWER OF SUPPLIERS 72
5.12.4 BARGAINING POWER OF BUYERS 72
5.12.5 DEGREE OF COMPETITION 72
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 72
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 72
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS 72
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%) 73
5.13.2 BUYING CRITERIA 73
FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 73
TABLE 11 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 73
5.14 CASE STUDY ANALYSIS 74
TABLE 12 CASE STUDY: ENHANCING PATIENT SAFETY—RT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC) 74
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 74
FIGURE 31 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 74
6 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE 75
6.1 INTRODUCTION 76
TABLE 13 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 76
6.2 PRODUCTS 76
TABLE 14 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 76
TABLE 15 PARTICLE THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 77
6.2.1 CYCLOTRONS 77
6.2.1.1 Advantages offered by cyclotrons over other accelerators to drive market 77
TABLE 16 CYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 78
TABLE 17 NORTH AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 18 EUROPE: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 19 ASIA PACIFIC: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 20 LATIN AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.2.2 SYNCHROTRONS 79
6.2.2.1 Increasing investments for development of synchrotron facilities to aid market growth 79
TABLE 21 SYNCHROTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 80
TABLE 22 NORTH AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 23 EUROPE: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 24 ASIA PACIFIC: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 25 LATIN AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
6.2.3 SYNCHROCYCLOTRONS 81
6.2.3.1 High space requirements to limit adoption 81
TABLE 26 SYNCHROCYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
TABLE 27 NORTH AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 28 EUROPE: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 29 ASIA PACIFIC: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 30 LATIN AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
6.3 SERVICES 84
6.3.1 AVAILABILITY OF WIDE RANGE OF SERVICES TO PROPEL MARKET 84
TABLE 31 PARTICLE THERAPY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 32 NORTH AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 33 EUROPE: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 34 ASIA PACIFIC: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 35 LATIN AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
7 PARTICLE THERAPY MARKET, BY TYPE 87
7.1 INTRODUCTION 88
TABLE 36 PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 88
7.2 PROTON THERAPY 88
7.2.1 GROWING ADOPTION AS PRIMARY TREATMENT FOR VARIOUS CANCER TYPES TO DRIVE MARKET 88
TABLE 37 PROTON THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 89
7.3 HEAVY ION THERAPY 89
7.3.1 SLOWER GROWTH ATTRIBUTED TO EXPERIMENTAL PHASE ACROSS MANY REGIONS 89
TABLE 38 HEAVY ION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 90
8 PARTICLE THERAPY MARKET, BY SYSTEM 91
8.1 INTRODUCTION 92
TABLE 39 PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 92
8.2 MULTI-ROOM SYSTEMS 92
8.2.1 LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES TO DRIVE INTEREST AMONG END USERS 92
TABLE 40 PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 93
8.3 SINGLE-ROOM SYSTEMS 93
8.3.1 COMPACT STRUCTURE AND REDUCED CAPITAL COST TO PROPEL GROWTH 93
TABLE 41 PARTICLE THERAPY MARKET FOR SINGLE-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 94
9 PARTICLE THERAPY MARKET, BY APPLICATION 95
9.1 INTRODUCTION 96
TABLE 42 PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96
9.2 TREATMENT APPLICATIONS 96
9.2.1 INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTERS TO SUPPORT MARKET GROWTH 96
TABLE 43 PARTICLE THERAPY MARKET FOR TREATMENT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 97
9.3 RESEARCH APPLICATIONS 97
9.3.1 INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS TO PROVIDE GROWTH OPPORTUNITIES 97
TABLE 44 PARTICLE THERAPY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 98
10 PARTICLE THERAPY MARKET, BY CANCER TYPE 99
10.1 INTRODUCTION 100
TABLE 45 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 100
10.2 PEDIATRIC CANCER 100
10.2.1 INCREASING CASES OF PEDIATRIC CANCER TO PROPEL MARKET 100
TABLE 46 PARTICLE THERAPY MARKET FOR PEDIATRIC CANCER, BY REGION, 2021–2028 (USD MILLION) 101
10.3 PROSTATE CANCER 101
10.3.1 ADVANTAGES OFFERED BY PARTICLE THERAPY FOR TREATMENT OF PROSTATE CANCER TO DRIVE MARKET 101
TABLE 47 PARTICLE THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 102
10.4 LUNG CANCER 102
10.4.1 GROWING CLINICAL TESTING OF PROTON THERAPY FOR LUNG CANCER TO DRIVE MARKET 102
TABLE 48 PARTICLE THERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 102
10.5 BREAST CANCER 103
10.5.1 LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-EFFECTS TO INCREASE ADOPTION OF PARTICLE THERAPY 103
TABLE 49 PARTICLE THERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 103
10.6 HEAD & NECK CANCER 103
10.6.1 USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY TO SUPPORT MARKET GROWTH 103
TABLE 50 PARTICLE THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2021–2028 (USD MILLION) 104
10.7 OTHER CANCERS 104
TABLE 51 PARTICLE THERAPY MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 104
11 PARTICLE THERAPY MARKET, BY REGION 105
11.1 INTRODUCTION 106
TABLE 52 PARTICLE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 106
11.2 NORTH AMERICA 106
11.2.1 NORTH AMERICA: RECESSION IMPACT 106
FIGURE 32 NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT 107
TABLE 53 NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 54 NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 55 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 108
TABLE 56 NORTH AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 57 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 109
TABLE 58 NORTH AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 109
TABLE 59 NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
11.2.2 US 110
11.2.2.1 Growing number of particle therapy centers to drive market growth 110
TABLE 60 US: MACROECONOMIC INDICATORS 111
TABLE 61 US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 111
TABLE 62 US: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
11.2.3 CANADA 112
11.2.3.1 Government initiative to include particle therapy as treatment method to boost market 112
TABLE 63 CANADA: MACROECONOMIC INDICATORS 112
TABLE 64 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 113
TABLE 65 CANADA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
11.3 EUROPE 113
11.3.1 EUROPE: RECESSION IMPACT 114
TABLE 66 EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 67 EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 68 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 115
TABLE 69 EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 70 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 115
TABLE 71 EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 116
TABLE 72 EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 116
11.3.2 GERMANY 116
11.3.2.1 Increasing research on proton and heavy ion therapy to drive market growth 116
TABLE 73 GERMANY: MACROECONOMIC INDICATORS 117
TABLE 74 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 117
TABLE 75 GERMANY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
11.3.3 FRANCE 118
11.3.3.1 Increasing healthcare expenditure to support particle therapy product adoption 118
TABLE 76 FRANCE: MACROECONOMIC INDICATORS 118
TABLE 77 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 119
TABLE 78 FRANCE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
11.3.4 UK 119
11.3.4.1 Increasing acceptance of particle therapy techniques in cancer treatment to support market growth 119
TABLE 79 UK: MACROECONOMIC INDICATORS 120
TABLE 80 UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120
TABLE 81 UK: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
11.3.5 ITALY 121
11.3.5.1 Increasing awareness activities to support market growth 121
TABLE 82 ITALY: MACROECONOMIC INDICATORS 121
TABLE 83 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 122
TABLE 84 ITALY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
11.3.6 SPAIN 122
11.3.6.1 Increasing number of conferences and government funding for cancer research to drive market 122
TABLE 85 SPAIN: MACROECONOMIC INDICATORS 123
TABLE 86 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 124
TABLE 87 SPAIN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
11.3.7 REST OF EUROPE 124
TABLE 88 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 125
TABLE 89 REST OF EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
11.4 ASIA PACIFIC 125
11.4.1 ASIA PACIFIC: RECESSION IMPACT 126
FIGURE 33 ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT 127
TABLE 90 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 91 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 92 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 128
TABLE 93 ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 94 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 129
TABLE 95 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 129
TABLE 96 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 130
11.4.2 JAPAN 130
11.4.2.1 Increasing use of heavy ion therapy for cancer treatment to propel market 130
TABLE 97 JAPAN: MACROECONOMIC INDICATORS 131
TABLE 98 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 131
TABLE 99 JAPAN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
11.4.3 CHINA 132
11.4.3.1 High cancer burden to drive market 132
TABLE 100 CHINA: MACROECONOMIC INDICATORS 132
TABLE 101 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 133
TABLE 102 CHINA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
11.4.4 INDIA 133
11.4.4.1 Improving research capabilities to support market growth 133
TABLE 103 INDIA: MACROECONOMIC INDICATORS 134
TABLE 104 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134
TABLE 105 INDIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
11.4.5 AUSTRALIA 135
11.4.5.1 Healthcare funding availability to boost market growth 135
TABLE 106 AUSTRALIA: MACROECONOMIC INDICATORS 135
TABLE 107 AUSTRALIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 135
TABLE 108 AUSTRALIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
11.4.6 SOUTH KOREA 136
11.4.6.1 Rising prevalence of cancer to drive market 136
TABLE 109 SOUTH KOREA: MACROECONOMIC INDICATORS 137
TABLE 110 SOUTH KOREA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 137
TABLE 111 SOUTH KOREA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
11.4.7 REST OF ASIA PACIFIC 138
TABLE 112 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 138
TABLE 113 REST OF ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
11.5 LATIN AMERICA 139
11.5.1 LATIN AMERICA: RECESSION IMPACT 139
TABLE 114 LATIN AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 115 LATIN AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 116 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 140
TABLE 117 LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 118 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 141
TABLE 119 LATIN AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 141
TABLE 120 LATIN AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
11.5.2 BRAZIL 142
11.5.2.1 Government initiates to propel market growth 142
TABLE 121 BRAZIL: MACROECONOMIC INDICATORS 142
TABLE 122 BRAZIL: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 143
TABLE 123 BRAZIL: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
11.5.3 MEXICO 143
11.5.3.1 Growing adoption of advanced medical technologies to drive market 143
TABLE 124 MEXICO: MACROECONOMIC INDICATORS 144
TABLE 125 MEXICO: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 144
TABLE 126 MEXICO: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
11.5.4 REST OF LATIN AMERICA 145
TABLE 127 REST OF LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
TABLE 128 REST OF LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
11.6 MIDDLE EAST & AFRICA 146
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET 146
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 146
TABLE 129 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 130 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 147
TABLE 131 MIDDLE EAST & AFRICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 132 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 148
TABLE 133 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 148
TABLE 134 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148
12 COMPETITIVE LANDSCAPE 149
12.1 OVERVIEW 149
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 150
FIGURE 34 KEY DEVELOPMENTS IN PARTICLE THERAPY MARKET 150
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 151
FIGURE 35 REVENUE ANALYSIS OF TOP PLAYERS IN PARTICLE THERAPY MARKET 151
12.4 MARKET SHARE ANALYSIS 152
FIGURE 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 152
12.5 COMPANY EVALUATION MATRIX 153
12.5.1 STARS 153
12.5.2 EMERGING LEADERS 153
12.5.3 PERVASIVE PLAYERS 153
12.5.4 PARTICIPANTS 153
FIGURE 37 PARTICLE THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022 154
12.6 COMPETITIVE BENCHMARKING FOR KEY PLAYERS 155
12.6.1 PARTICLE THERAPY MARKET: COMPANY FOOTPRINT 155
TABLE 135 OVERALL COMPANY FOOTPRINT (10 COMPANIES) 155
TABLE 136 TYPE FOOTPRINT (10 COMPANIES) 155
TABLE 137 PRODUCT & SERVICE FOOTPRINT (10 COMPANIES) 156
TABLE 138 SYSTEM FOOTPRINT (10 COMPANIES) 157
TABLE 139 CANCER TYPE FOOTPRINT (10 COMPANIES) 157
TABLE 140 APPLICATION FOOTPRINT (10 COMPANIES) 158
TABLE 141 REGIONAL FOOTPRINT (10 COMPANIES) 159
12.7 STARTUP/SME EVALUATION MATRIX 160
12.7.1 PROGRESSIVE COMPANIES 160
12.7.2 RESPONSIVE COMPANIES 160
12.7.3 DYNAMIC COMPANIES 160
12.7.4 STARTING BLOCKS 160
FIGURE 38 PARTICLE THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022 161
12.7.5 COMPETITIVE BENCHMARKING FOR STARTUPS/SMES 162
TABLE 142 OVERALL COMPANY FOOTPRINT 162
TABLE 143 TYPE FOOTPRINT 162
TABLE 144 PRODUCT & SERVICE FOOTPRINT 162
TABLE 145 SYSTEM FOOTPRINT 163
TABLE 146 CANCER TYPE FOOTPRINT 163
TABLE 147 APPLICATION FOOTPRINT 163
TABLE 148 REGIONAL FOOTPRINT 163
12.8 COMPETITIVE SCENARIOS & TRENDS 164
12.8.1 PRODUCT LAUNCHES & APPROVALS 164
TABLE 149 PARTICLE THERAPY MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−AUGUST 2023) 164
12.8.2 DEALS 164
TABLE 150 PARTICLE THERAPY MARKET: DEALS (JANUARY 2020−AUGUST 2023) 164
12.8.3 OTHER DEVELOPMENTS 166
TABLE 151 PARTICLE THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2020−AUGUST 2023) 166
13 COMPANY PROFILES 167
13.1 KEY PLAYERS 167
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 IBA WORLDWIDE 167
TABLE 152 IBA WORLDWIDE: BUSINESS OVERVIEW 167
FIGURE 39 IBA WORLDWIDE: COMPANY SNAPSHOT (2022) 168
13.1.2 VARIAN MEDICAL SYSTEMS, INC. 172
TABLE 153 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW 172
FIGURE 40 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022) 173
13.1.3 HITACHI, LTD. 176
TABLE 154 HITACHI, LTD.: BUSINESS OVERVIEW 176
FIGURE 41 HITACHI, LTD.: COMPANY SNAPSHOT (2021) 177
13.1.4 MEVION MEDICAL SYSTEMS 179
TABLE 155 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW 179
13.1.5 SUMITOMO HEAVY INDUSTRIES LTD. 182
TABLE 156 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW 182
FIGURE 42 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2021) 183
13.1.6 PROVISION HEALTHCARE, LLC 185
TABLE 157 PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW 185
13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION 186
TABLE 158 TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 186
FIGURE 43 TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022) 187
13.1.8 OPTIVUS PROTON THERAPY, INC. 188
TABLE 159 OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW 188
13.1.9 PROTOM INTERNATIONAL, INC. 189
TABLE 160 PROTOM INTERNATIONAL, INC.: BUSINESS OVERVIEW 189
13.1.10 ADVANCED ONCOTHERAPY PLC 190
TABLE 161 ADVANCED ONCOTHERAPY PLC: BUSINESS OVERVIEW 190
13.2 OTHER PLAYERS 191
13.2.1 DANFYSIK A/S 191
TABLE 162 DANFYSIK A/S: BUSINESS OVERVIEW 191
13.2.2 P-CURE, LTD. 192
TABLE 163 P-CURE, LTD.: BUSINESS OVERVIEW 192
13.2.3 PTW FREIBURG GMBH 193
TABLE 164 PTW FREIBURG GMBH: BUSINESS OVERVIEW 193
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
14 APPENDIX 194
14.1 DISCUSSION GUIDE 194
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 199
14.3 CUSTOMIZATION OPTIONS 201
14.4 RELATED REPORTS 201
14.5 AUTHOR DETAILS 202

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の粒子線療法市場（～2028年）：種類別（陽子線治療、重粒子線治療）、製品別（サイクロトロン、シンクロトロン、シンクロサイクロトロン）、サービス別、システム別（シングルルーム、マルチルーム）、がん種類別（小児がん、前立腺がん）、用途別（治療、研究）(Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp